ILLUMINA: Excerpt from fund letter on company’s market share and temporary sales impact in China
July 20, 2022
Trending News 🌥️
Illumina ($NASDAQ:ILMN) is a leading provider of gene sequencing technology and equipment. The company has a 90% market share in this key area, which enables a wide range of genetic research and clinical applications. However, sales in China have been temporarily impacted by the COVID-related shutdowns in the country. It is unclear how long the impact of the COVID shutdowns will last in China, but it is reasonable to believe that Illumina will eventually resume its strong growth trajectory. The company’s dominant market position and strong product offerings should allow it to continue to be a leader in the gene sequencing space in the long term.
Market Reaction
Illumina is a leading provider of next-generation sequencing solutions. Following the release of the letter, Illumina’s stock price has mostly been mixed.
However, on Tuesday, the stock opened at $191.3 and closed at $194.6, up 3.9% from the previous closing price of $187.3. Overall, the company remains confident in its long-term prospects, despite the temporary sales impact in China.
VI Analysis
Company’s fundamentals reflect its long term potential, below analysis on ILLUMINA are made simple by VI app. The fair value of ILLUMINA share is around $405.8, calculated by VI Line. Now ILLUMINA stock is traded at $194.6, undervalued by 52%.
Summary
Based on the mixed news, investing in ILLUMINA would be a good idea. The company has a strong market share, and although there may be some temporary sales impact in China, the company will rebound quickly.
